formodual 100 mikrogramm/6 mikrogramm túlnyomásos inhalációs oldat
chiesi pharmaceuticals gmbh - beclometasone; formoterol -
foster 100 mikrogramm/6 mikrogramm túlnyomásos inhalációs oldat
chiesi pharmaceuticals gmbh - beclometasone; formoterol -
foster 200 mikrogramm/6 mikrogramm túlnyomásos inhalációs oldat
chiesi pharmaceuticals gmbh - beclometasone; formoterol -
vivaire 100 mikrogramm/6 mikrogramm túlnyomásos inhalációs oldat
zentiva, k.s. (csehország) - beclometasone dipropionate; formoterol fumarate dihydrate -
foster nexthaler 100 mikrogramm/6 mikrogramm/belégzés inhalációs por
chiesi pharmaceuticals gmbh - beclometasone; formoterol -
foster nexthaler 200 mikrogramm/ 6 mikrogramm/belégzés inhalációs por
chiesi pharmaceuticals gmbh - beclometasone; formoterol -
foster nexthaler 200 mikrogramm/12 mikrogramm/belégzés inhalációs por
chiesi pharmaceuticals gmbh - beclometasone dipropionate; formoterol fumarate dihydrate -
beclonasal aqua 50 mikrogramm/dózis szuszpenziós orrspray
orion corporation - beclometasone -
sabacomb 250 mikrogramm/100 mikrogramm túlnyomásos inhalációs szuszpenzió
chiesi pharmaceuticals gmbh - beclometasone dipropionate, vízmentes; szalbutamol-szulfát -
trimbow
chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol-fumarát dihidrát, glycopyrronium-bromid - tüdőbetegség, krónikus obstruktív - gyógyszerek obstruktív légúti betegségek, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.